XIN YAN
Department of Mathematics and Statistics
University of Missouri-Kansas City
yanxi@umkc.edu
EDUCATION
May, 1998.
Ph.D in Statistics, University of California at Davis
June, 1994. M.S
in Statistics, University of California at Davis
Feb., 1982.
in Mathematics, China University of Geosciences
B.S
PROFESSIONAL APPOINTMENTS
ASSOCIATE PROFESSOR OF STATISTICS WITH TENURE, Department of
Mathematics and Statistics, University Missouri-Kansas City, September, 2006 − present.
SENIOR BIOMETRICIAN, Department of Clinical Biostatistics, Merck Research Laboratories.
August, 2001− August 2006.
SENIOR BIOSTATISTICIAN, Department of Biostatistics, GlaxoSmithKline, June, 1998
−August, 2001.
TEACHING ASSISTANT, Department of Statistics, UC Davis. September, 1993 − May,
1998.
TEACHING
Introduction to Mathematical Statistics(Stat436), Fall, 2006, Spring and Fall 2007, 2008, 2009.
Regression Analysis(Stat5654) (graduate course), Spring, 2007, 2008, 2009.
Introduction to Statistics(Stat235), Fall 2007, Spring and Fall, 2008, 2009.
Theory of Linear Models(Stat5590) (graduate course), Fall 2009.
Mathematical Statistics I(Stat5537) (graduate course), Fall 2010.
Mathematical Statistics II(Stat5547) (graduate course), Spring 2011.
1
PUBLISED PAPERS
1. Yan, X.(2009), Stratified Wilson and Newcombe Confidence Intervals for Multiple
Binomial Proportions, Journal of Biopharmaceutical Research, to appear.
2. Yan, X. (2008), Book Review: Linear Models: An Integrated Approach. J. of American
Statistical Association. Vol. 103, Number 482, June, 884-885.
3. X. G. Su and Yan. X. (2008), Tree-Structured Subgroup Analysis with Censored Survival
Data, The International Journal of Biostatistics, Vol. 4, Issue 1, 1-26.
4. Rekab, K. Yan, X., Thomas, H. H. (2008), An efficient sampling scheme for estimating
software reliability with associated cost, FJMS, Vol. 28, Issue 2, 353-366.
5. Yan, X. and Anthony Homer (2007), Cochran-Mantel-Haenszel confidence interval with
Laplace correction in the comparison of two high rates, JP Journal of Biostatistics, Vol. 1,
No. 2, 205-115.
6. Rekab, K., Yan, X. and Fauls, M. (2007), Asymptotic optimality of fully sequential design
and stochastic stopping rule for Myopic design. International Journal of Mathematics and
Computer Sciences, 2, 41-48.
7. Rekab, K., Yan, X. (2007), Two-stage, best-fixed and accelerated designs for software
reliability test. Far East Journal of Theoretical Statistics, 20(2), 207-216.
8. Yan, X., Wang, M. and Su, X. G. (2007). Test for consistency of non-inferiority from
multiple non-inferiority trials. Journal of Biopharmaceutical Statistics, 17, 1-14.
9. Yan, X and Su, X. G. (2006). Sample size determination for clinical trials in patients with
longitudinal nonlinear disease progression, Journal of Biopharmaceutical Statistics, 16, 115.
10. Su, X. G., Cai, C. L. and Yan, X. (2006). Treed variance, Journal of Statistics Computing
and Graphics, 15, No.2, 356-371.
11. Myron J. Levin, Yan. X, et al. (2006). Dose-Ranging Safety and Immunogenicity study of
live attenuated varicella-zoster virus vaccine (Oka/Merck) administered to adults 60 years
of age or older.: GER-3. Southern Medical Journal. 98 (10), Supplement: S55.
12. Yan, X. and Su, X. G. (2005). Test for qualitative interaction, Encyclopedia of
Biopharmaceutical Statistics, Second Edition, John Wiley & Sons.
2
13. Yan, X. (2004). Test for qualitative treatment-by-center interaction in equivalence trials
when the number of centers is large, Statistics in Medicine, 23, 711-722.
14. Mueller, H. G. and Yan, X. (2001). On local moments, Journal of Multivariate Analysis,
Vol. 76, 90-109.
15. Yan, X. (1997). Modeling time to multiple events using the frailty model in patients with
cystic fibrosis. Technical Report, P.1-50, Genentech, Inc.
PAPERS IN PREPARATION
16. Yan. X. Bias-corrected Estimation and Confidence interval for Proportion ratio and
Stratified Proportion Ratios (2009). In preparation.
17. Yan, X. and Su, X. G. Simultaneous inference on all linear combinations of
multiple means in the case of unequal variances (2009). In preparation.
18. Yan, X and Breadstreet, Efficacy assessment of cough-modifying agents based on
the correlated singly left-truncated cough counts (2009), In preparation.
BOOK IN STATISTICS
Linear Regression Analysis: Theory and Computing, Yan, X, and Su, X. G.,
ISBN-13: 9789812834102, World Journal Scientific Publisher.
EDITORIAL WORK
Editorial Board Member of JP Journal of Biostatistics since 2008
RESEARCH IN VARIOUS CLINICAL TRIALS
Statistician for various clinical trials of vaccine and drug products such as PROQUAD,
VAQTA, ZOSVAX, VRIVAX, ARIFLO, PEDIACEL, VITROS, Rivaroxiban currently
in active use for treatment and prevention of various diseases.
1. Stratified statistical analysis methods for the evaluation of the immunogenicity of
30 vaccine trials to prevent the pertussis disease for the regulatory submission in
the European countries (2007).
3
2. Integrated statistical analysis plan (IAP-I) for the analysis of immunogenicity and
efficacy of 30 clinical trials of the 5-component multivalent pertussis vaccines for
the regulatory filing in the European countries (2007)
3. A double-blind, randomized pilot study to characterize the cough response to
inhaled capsaicin in healthy male smoker and to establish and compare the
capsaicin induced cough responses in healthy smokers following a single dose of
morphine, dexbromphenriramine, and placebo (2006).
4. A 3-period double-blind, randomized, placebo-controlled, single oral dose
crossover study to evaluate the safety, tolerability, pharmacodynamics, and
pharmacokinetics for skin pain relief in healthy male subjects (2006).
5. A 2-part, double-blind, randomized, placebo-controlled, single oral rising-dose
study to evaluate and safety, tolerability, pharmacokinetics, and preliminary
pharmacodynamics study for skin pain relief in health male subjects (2006).
6. A 3-Period, double-blind, randomized, placebo-controlled, rising, single, oral dose
to evaluate the safety, tolerability, and pharmacokinetics for cough responses in
healthy elderly subjects (2006).
7. A double-blind, placebo-controlled, sequential panel, rising multiple oral dose
study to evaluate the safety, tolerability, and pharmacokinetics for skin pain relief
in healthy male subjects (2006).
8. Concomitant use of multiple vaccines Vaqta, Prevnar, and ProQuad to determine
an efficient vaccination scheme and to improve prevention of multiple targeted
diseases in the United States (2005).
9. Concomitant use of multiple vaccines Vaqta, Pedvax and Varivax to provide an
efficient vaccination scheme and to improve prevention of multiple targeted
diseases in the United States (2005).
10. Safety evaluation on concomitant use of vaccines Vaqta, ProQuad, and Varivax in
children of 12-month of age (2005).
11. Clinical study report on serological persistence follow-up in children of 6-year of
age after initial hepatitis A vaccination (2005).
12. Clinical study report on serological persistence follow-up in children of 10 year of
age after initial hepatitis A vaccination (2005).
4
13. Clinical study report on safety and efficacy confirmatory trial in healthy children
who received hepatitis A vaccine Vaqta at 6-month of age (2005).
14. Clinical study report on 10-year varicella breakthrough in recipients of 1991
production lots of varicella vaccine (2004).
15. Clinical study report on efficacy assessment to compare the 1-dose with the 2-dose
varicella vaccination for the recommendation on the 2-dose varicella vaccination
scheme in the United States (2004).
16. Clinical study report on persistence of measles, mumps, rubella and varicella
antibodies in healthy children 1 year post vaccination with ProQuad or M-M-R II
and Varivax (2003).
17. Clinical study report on dose-ranging and safety and immunogenicity study of live
attenuated herpes-zoster virus vaccine (Oka/Merck) administered to adults 60
years of age or older (2003).
18. Clinical study report on the PUVV 32 (new master seeds) process upgrade vaccine
for varicella disease (2002).
19. Interim clinical study report on a comparison of the safety, tolerability, and
immunogenicity of M-M-R II manufactured with recombinant human albumin
(rHA) versus M-M-R II manufactured with pooled-donor human serum albumin
(HAS) in healthy children 12 to 18 months of age (2002).
20. Clinical study report on safety and efficacy assessment of consistency lots of a
multivalent vaccine MMRV (measles, mumps, rubella and varicella) (2001).
21. Concomitant use of multivalent vaccine ProQuad and Prevnar for healthy children
of 12 years of age and older (2001).
22. Clinical study report on safety and efficacy of clinical trial in patients with chronic
obstructive pulmonary disease (COPD) (2000).
23. Clinical trial of long term efficacy follow-up in patients with chronic obstructive
pulmonary disease (COPD) (2000).
24. Clinical trial to assess both efficacy and safety in women with osteoporosis (1999).
5
PROFESSIONAL PRESENTATIONS
1. Application of frailty model in the analysis of clinical trials with patients in
chronic obstructive pulmonary disease. Biometrics Department, GSK, 2001.
2. Application of pattern mixture model in longitudinal trials in patients with cystic
fibrosis, Biostatistics Research Seminar, GSK, 2002.
3. Test for qualitative patient-by-treatment interaction in large multi-center phase
III clinical trials. Department of Statistics, University of Central Florida, 2003,
Invited.
4. Test for treatment efficacy in large scale equivalence clinical trail, Biostatistics
Department, Aventis, 2004.
5. Overview of treatment-by-patient-subset interaction in clinical trials, Department
of Medical Affairs, Genentech, 2005, Invited.
6. Approximation method of simultaneous confidence intervals on means with
heteroscadastic variances, Graduate Seminar, Department of Mathematics and
Statistics at UMKC, 2006.
7. Maximum Likelihood estimate of marginally left-truncated Poisson cough
counts: a direct method for assessment of cough treatment in experimental
medicine, Joint Annual Statistical Meeting of American Statistical Association,
Salt Lake City, 2007.
8. Generalized Scheffe’s simultaneous confidence intervals with applications in
multiple non-inferiority clinical trials, The 15th International Conference of
Forum for Interdisciplinary Mathematics and Statistics, 2007.
9. Accelerated two-stage sequential design for software reliability estimation. The
15th International Conference of Forum for Interdisciplinary Mathematics and
Statistics, 2007.
10. Cochran-Mantel-Haenszel confidence interval with Laplace Correction and its
applications in high protective multivalent vaccine. Biostatistics Platform,
Sanofi-Pasteur, 2007.
11. Stratified Wilson and Newcombe-Wilson confidence intervals for a single
binomial proportion and the difference in two binomial proportions. Sanofi,
2007.
6
12. Statistical issues and regulatory requirements related to the assessment of
multiple binomial proportions and proportion differences in multi-center clinical
trials. The first international symposium of biopharmaceutical statistics, 2008,
Invited,
PROFESSIONAL SERVICES

Chair of the faculty search committee (2006)

Member of departmental tenure and promotion committee (2006-present)

Invited research proposal reviewer for Kansas Life Sciences Institute

Book reviewer for the Journal of American Statistical Association, Statistics
in Medicine, Journal of Biopharmaceutical Statistics, etc.
PROFESSIONAL AFFILIATION
Member of American Statistical Association since 1995
7